0000000000601513

AUTHOR

Veronica Huber

showing 7 related works from this author

Fasting-Mimicking Diet Is Safe and Reshapes Metabolism and Antitumor Immunity in Patients with Cancer.

2021

Abstract In tumor-bearing mice, cyclic fasting or fasting-mimicking diets (FMD) enhance the activity of antineoplastic treatments by modulating systemic metabolism and boosting antitumor immunity. Here we conducted a clinical trial to investigate the safety and biological effects of cyclic, five-day FMD in combination with standard antitumor therapies. In 101 patients, the FMD was safe, feasible, and resulted in a consistent decrease of blood glucose and growth factor concentration, thus recapitulating metabolic changes that mediate fasting/FMD anticancer effects in preclinical experiments. Integrated transcriptomic and deep-phenotyping analyses revealed that FMD profoundly reshapes antican…

MaleMyeloidmedicine.medical_treatmentAntineoplastic AgentsBreast NeoplasmsPharmacologyTranscriptomeImmune systemmedicineCytotoxic T cellHumansProspective Studiesbusiness.industryGrowth factorCancerMetabolismFastingMiddle Agedmedicine.diseaseClinical trialmedicine.anatomical_structureTreatment OutcomeOncologyFemalebusinessColorectal NeoplasmsCancer discovery
researchProduct

Circulating mir-320a promotes immunosuppressive macrophages M2 phenotype associated with lung cancer risk

2019

miRNAs play a central role in the complex signaling network of cancer cells with the tumor microenvironment. Little is known on the origin of circulating miRNAs and their relationship with the tumor microenvironment in lung cancer. Here, we focused on the cellular source and relative contribution of different cell types to circulating miRNAs composing our risk classifier of lung cancer using in vitro/in vivo models and clinical samples. A cell‐type specific expression pattern and topography of several miRNAs such as mir‐145 in fibroblasts, mir‐126 in endothelial cells, mir‐133a in skeletal muscle cells was observed in normal and lung cancer tissues. Granulocytes and platelets are the major …

MaleCancer ResearchCell typeLung NeoplasmsCarcinogenesisNeutrophilsMacrophageMice SCIDBiologymedicine.disease_causeMolecular Cancer Biology03 medical and health sciencesParacrine signallingMice0302 clinical medicineImmune systemCell Line TumormicroRNAmedicineTobacco SmokingAnimalsHumansCirculating MicroRNALung cancerLungCarcinogenesiTumor microenvironmentmicroRNAAnimalMacrophagesGene Expression ProfilingNeutrophilSTAT4 Transcription Factormedicine.diseasemicroenvironmentXenograft Model Antitumor Assays3. Good healthGene Expression Regulation NeoplasticLung NeoplasmMicroRNAslung cancerOncology030220 oncology & carcinogenesisCancer cellCancer researchFemaleTumor EscapeCarcinogenesisHuman
researchProduct

P2.01-017 Circulating miRNAs in Lung Cancer Are Associated to Pro-Tumorigenic and Immunosuppressive Microenvironment

2017

Pulmonary and Respiratory MedicineCirculating mirnasOncologybusiness.industryCancer researchMedicineRNAbusinessTopic analysisLung cancermedicine.diseaseJournal of Thoracic Oncology
researchProduct

Abstract 4981: Circulating mir-320 promotes immunosuppressive macrophages M2 phenotype associated with lung cancer progression

2018

Abstract INTRODUCTION miRNAs play a role in the complex network of signaling between cancer cells and tumor microenvironment. We previously reported the identification of diagnostic miRNA signatures (MSC) based on 24-miRNAs in plasma samples of lung cancer patients detected by low dose computed tomography (LDCT) screening. MATERIAL and METHODS To evaluate the potential origin of the miRNAs of the diagnostic signature, we analyzed their expression by real-time or digital PCR in both cells and conditioned medium (CM) from different cell types of the lung microenvironment as well as in plasma samples of heavy smokers and patients. Lung tissues and cell-blocks were analyzed by miRNAs in situ hy…

Cancer ResearchTumor microenvironmentCancerIn situ hybridizationBiologymedicine.diseasemedicine.disease_causeParacrine signallingOncologyCancer cellmicroRNACancer researchmedicineCarcinogenesisLung cancerCancer Research
researchProduct

Antibody–Fc/FcR Interaction on Macrophages as a Mechanism for Hyperprogressive Disease in Non–small Cell Lung Cancer Subsequent to PD-1/PD-L1 Blockade

2019

Abstract Purpose: Hyperprogression (HP), a paradoxical boost in tumor growth, was described in a subset of patients treated with immune checkpoint inhibitors (ICI). Neither clinicopathologic features nor biological mechanisms associated with HP have been identified. Experimental Design: Among 187 patients with non–small cell lung cancer (NSCLC) treated with ICI at our institute, cases with HP were identified according to clinical and radiologic criteria. Baseline histologic samples from patients treated with ICI were evaluated by IHC for myeloid and lymphoid markers. T-cell–deficient mice, injected with human lung cancer cells and patient-derived xenografts (PDX) belonging to specific mutat…

0301 basic medicineMaleCancer ResearchMyeloidLung NeoplasmsCD33Programmed Cell Death 1 ReceptorFc receptorMice NudeMice SCIDReceptors Fcnon-small cell lung cancer Hyperprogression immune checkpoint inhibitors.B7-H1 AntigenArticle03 medical and health sciences0302 clinical medicineImmunophenotypingAntineoplastic Agents ImmunologicalPD-L1Carcinoma Non-Small-Cell LungCell Line TumormedicineAnimalsHumansLung cancerAntibodies Blockingbiologybusiness.industryMacrophagesmedicine.diseaseXenograft Model Antitumor Assays3. Good healthImmunoglobulin Fc FragmentsTumor Burden030104 developmental biologymedicine.anatomical_structureNivolumabOncology030220 oncology & carcinogenesisbiology.proteinCancer researchImmunohistochemistryFemaleAntibodybusinessClinical Cancer Research
researchProduct

P2.04-11 An IL-8/IFN-gammma/NLR Plasma Score to Predict Nivolumab Efficacy in Patients with NSCLC

2018

Pulmonary and Respiratory MedicineOncologymedicine.medical_specialtyOncologybusiness.industryInternal medicineMedicineIn patientInterleukin 8NivolumabbusinessJournal of Thoracic Oncology
researchProduct

Minimal information for studies of extracellular vesicles 2018 (MISEV2018):a position statement of the International Society for Extracellular Vesicl…

2018

The last decade has seen a sharp increase in the number of scientific publications describing physiological and pathological functions of extracellular vesicles (EVs), a collective term covering various subtypes of cell-released, membranous structures, called exosomes, microvesicles, microparticles, ectosomes, oncosomes, apoptotic bodies, and many other names. However, specific issues arise when working with these entities, whose size and amount often make them difficult to obtain as relatively pure preparations, and to characterize properly. The International Society for Extracellular Vesicles (ISEV) proposed Minimal Information for Studies of Extracellular Vesicles ("MISEV") guidelines fo…

ectosomeectosomes; exosomes; extracellular vesicles; guidelines; microparticles; microvesicles; minimal information requirements; reproducibility; rigor; standardization; Histology; Cell Biology[SDV]Life Sciences [q-bio]minimal information requirementsectosomes; exosomes; extracellular vesicles; guidelines; microparticles; microvesicles; minimal information requirements; reproducibility; rigor; standardizationsize-exclusionectosomesMedicine and Health SciencesCELL-DERIVED MICROPARTICLESFIELD-FLOW FRACTIONATIONguidelinesrequirementscirculatingComputingMilieux_MISCELLANEOUSmicroparticlesManchester Cancer Research Centrelcsh:Cytologyextracellular vesicles; exosomes; ectosomes; microvesicles; minimal information requirements; guidelines; standardization; microparticles; rigor; reproducibilityPROSTATE-CANCERmicroparticleCell interactionmicrovesiclechromatographyPosition Paperextracellular vesiclesguidelineLife Sciences & Biomedicinemicrovesiclesectosomes exosomes extracellular vesicles guidelines microparticles microvesicles minimal information requirements reproducibility rigor standardizationMEMBRANE-VESICLESHistologyFETAL BOVINEEctosomes ; Exosomes ; Extracellular Vesicles ; Guidelines ; Microparticles ; Microvesicles ; Minimal Information Requirements ; Reproducibility ; Rigor ; StandardizationCIRCULATING MICROPARTICLES[SDV.BC]Life Sciences [q-bio]/Cellular Biologyexosomesddc:570exosomeSURFACE-PLASMON RESONANCEddc:610lcsh:QH573-671BiologyreproducibilitystandardizationInteracció cel·lularScience & TechnologyResearchInstitutes_Networks_Beacons/mcrcCell BiologyrigorCell membranesHUMAN URINARY EXOSOMESPREANALYTICAL PARAMETERSminimal information requirementSIZE-EXCLUSION CHROMATOGRAPHY1182 Biochemistry cell and molecular biologyextracellular vesicleHuman medicineMembranes cel·lulars
researchProduct